IRIS Institutional Research Information System - OPENBS Open Archive UniBS

ANDREOLI, Laura
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.845
EU - Europa 7.186
AS - Asia 6.248
SA - Sud America 1.633
AF - Africa 145
OC - Oceania 21
Continente sconosciuto - Info sul continente non disponibili 17
AN - Antartide 1
Totale 27.096
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.666
DE - Germania 2.224
SG - Singapore 2.202
CN - Cina 1.810
BR - Brasile 1.382
UA - Ucraina 1.195
HK - Hong Kong 939
PL - Polonia 765
IT - Italia 751
RU - Federazione Russa 625
VN - Vietnam 444
FI - Finlandia 418
GB - Regno Unito 365
TR - Turchia 296
IE - Irlanda 235
FR - Francia 207
IN - India 122
AR - Argentina 98
BD - Bangladesh 90
CA - Canada 88
SE - Svezia 87
MX - Messico 62
ZA - Sudafrica 58
NL - Olanda 54
EC - Ecuador 47
IQ - Iraq 47
JP - Giappone 41
ID - Indonesia 40
ES - Italia 37
AT - Austria 36
CZ - Repubblica Ceca 28
PK - Pakistan 27
CO - Colombia 25
UZ - Uzbekistan 23
VE - Venezuela 23
EG - Egitto 22
MA - Marocco 22
SA - Arabia Saudita 21
AU - Australia 20
BE - Belgio 19
PY - Paraguay 17
AE - Emirati Arabi Uniti 15
CL - Cile 15
EU - Europa 15
JO - Giordania 15
CH - Svizzera 14
GR - Grecia 14
LT - Lituania 13
HR - Croazia 12
PE - Perù 12
IL - Israele 11
KE - Kenya 11
KZ - Kazakistan 11
MK - Macedonia 10
PH - Filippine 10
DK - Danimarca 9
PT - Portogallo 9
TH - Thailandia 9
NP - Nepal 8
RS - Serbia 8
SK - Slovacchia (Repubblica Slovacca) 8
UY - Uruguay 8
DZ - Algeria 7
HU - Ungheria 7
AL - Albania 6
BG - Bulgaria 6
ET - Etiopia 6
GE - Georgia 6
JM - Giamaica 6
KR - Corea 6
RO - Romania 6
BH - Bahrain 5
BO - Bolivia 5
DO - Repubblica Dominicana 5
LU - Lussemburgo 5
MY - Malesia 5
AZ - Azerbaigian 4
CR - Costa Rica 4
IR - Iran 4
KH - Cambogia 4
KW - Kuwait 4
LB - Libano 4
NO - Norvegia 4
PS - Palestinian Territory 4
AM - Armenia 3
BB - Barbados 3
CI - Costa d'Avorio 3
LK - Sri Lanka 3
LV - Lettonia 3
OM - Oman 3
PA - Panama 3
SN - Senegal 3
SY - Repubblica araba siriana 3
TN - Tunisia 3
BY - Bielorussia 2
HN - Honduras 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
LY - Libia 2
MD - Moldavia 2
Totale 27.070
Salva come PNG Salva come JPEG
Città #
Fairfield 1.489
Woodbridge 1.174
Singapore 993
Ashburn 987
Hong Kong 934
Jacksonville 830
Houston 825
Warsaw 757
Seattle 567
Cambridge 544
Wilmington 512
Ann Arbor 491
Beijing 448
Princeton 439
New York 355
Chandler 346
Helsinki 253
Istanbul 242
Dublin 235
Nanjing 226
Los Angeles 217
The Dalles 172
Ho Chi Minh City 150
Munich 149
São Paulo 133
Brescia 129
Dallas 117
Moscow 117
Redondo Beach 107
Nanchang 102
Nürnberg 102
San Diego 101
Des Moines 93
Buffalo 92
Hanoi 87
Changsha 85
Milan 80
Shanghai 78
Chicago 73
San Francisco 73
Shenyang 69
Hebei 65
Lancaster 62
London 55
Turku 52
Rio de Janeiro 49
Nuremberg 47
Santa Clara 45
Jinan 42
Tokyo 37
Belo Horizonte 34
Tianjin 33
Dearborn 32
Jiaxing 32
Johannesburg 32
Toronto 31
Hangzhou 30
Atlanta 28
Chennai 28
Porto Alegre 28
Zhengzhou 28
Bergamo 26
Brooklyn 26
Curitiba 26
Denver 25
Guangzhou 25
Phoenix 25
Brasília 24
Dong Ket 24
Poplar 24
Verona 24
Mexico City 23
Romola 23
Boardman 21
Dhaka 21
Kunming 21
Tashkent 21
Haiphong 20
Orem 19
Brno 18
Brussels 18
Lanzhou 18
Biên Hòa 17
Guayaquil 17
Montreal 17
Stockholm 16
Taizhou 16
Amman 15
Amsterdam 15
Charlotte 15
Da Nang 15
Goiânia 15
Rome 15
Falkenstein 14
Frankfurt am Main 14
Haikou 14
Juiz de Fora 14
Manchester 14
Ribeirão Preto 14
Ankara 13
Totale 16.505
Salva come PNG Salva come JPEG
Nome #
9A.07: CARDIOVASCULAR TARGET ORGAN DAMAGE IN PREMENOPAUSAL SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS AND IN CONTROLS. ARE THERE ANY DIFFERENCES? 318
Role of guanylate binding protein-1 in vascular defects associated with chronic inflammatory diseases. 281
EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome 272
The Pathogenicity of Anti-β2GP1-IgG Autoantibodies Depends on Fc Glycosylation 237
Long-term outcome of children of rheumatic disease patients 214
Aicardi-Goutieres syndrome, a rare neurological disease in children: a new autoimmune disorder? 213
Sine causa tetraparesis: A pilot study on its possible relationship with interferon signature analysis and Aicardi Goutières syndrome related genes analysis 212
SINDROME DA ANTICORPI ANTIFOSFOLIPIDI E LESIONI PUNTIFORMI DELLA SOSTANZA BIANCA ALLA RISONANZA MAGNETICA. QUAL E' IL LORO SIGNIFICATO? VALUTAZIONE DI 169 PAZIENTI CON MANIFESTAZIONI NEUROLOGICHE 199
14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome 188
Antirheumatic drugs and reproduction in women and men with chronic arthritis. 188
The role of second trimester uterine artery Doppler in pregnancies with systemic lupus erythematosus 185
Trichostatin A blocks type I interferon production by activated plasmacytoid dendritic cells. 180
COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case–control study 174
14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends 173
Effector T-cells are expanded in systemic lupus erythematosus patients with high disease activity and damage indexes 173
Anti-phospholipid antibodies 171
Children born to SLE and APS mothers 171
Typing TREX1 Gene In Patients With Systemic Lupus Erythematosus. 167
A comprehensive review of the clinical approach to pregnancy and systemic lupus erythematosus 167
First Report of the Italian Registry on Immune-Mediated Congenital Heart Block (Lu.Ne Registry) 167
Anti-IFI16 antibodies and their relation to disease characteristics in systemic lupus erythematosus. 166
Macrophage activation syndrome in adult systemic lupus erythematosus: Report of seven adult cases from a single Italian rheumatology center 165
Anti-cardiolipin and anti-beta2-glycoprotein I antibodies: performance of new commercial ELISA kits. 160
A 24-month prospective study on the efficacy and safety of two different monthly regimens of vitamin D supplementation in pre-menopausal women with systemic lupus erythematosus 159
Cardiovascular target organ damage in premenopausal systemic lupus erythematosus patients and in controls: Are there any differences? 158
Management of thrombotic and obstetric antiphospholipid syndrome: A systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults 157
25 years of the antiphospholipid syndrome: lights and shadows on the primary prophylaxis of asymptomatic patients with confirmed positivity of antiphospholipid antibodies. 154
Antiphospholipid antibodies mediate autoimmunity against dying cells. 154
Autoantibodies' titre modulation by anti-BlyS treatment in systemic lupus erythematosus. 153
Association Between Changes in BLyS Levels and the Composition of B and T Cell Compartments in Patients With Refractory Systemic Lupus Erythematosus Treated With Belimumab 152
Organ damage accrual and distribution in systemic lupus erythematosus patients followed-up for more than 10 years 151
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome 151
Patients with longstanding primary antiphospholipid syndrome: retrospective analysis of organ damage and mortality 149
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy 148
Pregnancy implications for systemic lupus erythematosus and the antiphospholipid syndrome 147
Longterm outcome of patients with primary antiphospholipid syndrome: A retrospective multicenter study 147
Inflammatory molecules: A target for treatment of systemic autoimmune diseases. 146
Validity of the rheumatoid arthritis impact of disease (RAID) score and definition of cut-off points for disease activity states in a population-based European cohort of patients with rheumatoid arthritis 146
Autoantibodies against galectin-2 peptides as biomarkers for the antiphospholipid syndrome. 144
Are the autoimmune/inflammatory syndrome induced by adjuvants (ASIA) and the undifferentiated connective tissue disease (UCTD) related to each other? A case-control study of environmental exposures 144
Beyond the "syndrome": antiphospholipid antibodies as risk factors. 143
The effects of lupus and antiphospholipid antibody syndrome on foetal outcomes 143
State of the art: Reproduction and pregnancy in rheumatic diseases. 143
Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome 143
Antiphospholipid antibody profile: implications for the evaluation and management of patients. 142
APS ACTION--AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking. 142
Exosome-delivered microRNAs promote IFN-α secretion by human plasmacytoid DCs via TLR7 141
PROSPECTIVELY FOLLOWED PREGNANCIES IN PATIENTS WITH SYSTEMIC VASCULITIS: STILL MANY PROBLEMS ON BOTH FOETAL AND MATERNAL SIDE 139
Phenotype modifications of T-cells and their shift toward a Th2 response in patients with systemic lupus erythematosus supplemented with different monthly regimens of vitamin D 139
Are the current attempts at standardization of antiphospholipid antibodies still useful? Emerging technologies signal a shift in direction. 138
Much more than thrombosis and pregnancy loss: the antiphospholipid syndrome as a 'systemic disease'. 138
Risk factors for adverse maternal and fetal outcomes in women with confirmed aPL positivity: Results from a multicenter study of 283 pregnancies 138
Antinucleosome antibodies in primary antiphospholipid syndrome: a hint at systemic autoimmunity? 137
Primary anti-phospholipid syndrome: any role for serum complement levels in predicting pregnancy complications? 137
Autoantibodies against galectins are associated with antiphospholipid syndrome in patients with systemic lupus erythematosus. 136
Systemic vasculitis and pregnancy: a multicenter study on maternal and neonatal outcome of 65 prospectively followed pregnancies 136
Management of recurrent thrombosis in antiphospholipid syndrome 135
High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: 'PROS' and 'CONS'. 134
EFFICACY AND SAFETY OF CYCLOSPORINE-A DURING PREGNANCY IN AUTOIMMUNE DISEASES 133
Predictors of maternal and fetal complications in SLE patients: a prospective study 133
ANTI-BETA2 GLYCOPROTEIN I-DOMAIN 1 AUTOANTIBODIES: COMPARISON BETWEEN TWO METHODS OF DETECTION 133
Exploring Autoimmunity in a Cohort of Children with Genetically Confirmed Aicardi–Goutières Syndrome 133
Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome 133
European multicentre pilot survey to assess vitamin D status in rheumatoid arthritis patients and early development of a new Patient Reported Outcome questionnaire (D-PRO) 133
Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. 133
Anti-inflammatory action of colchicine in hospitalised patients with COVID-19. Response to: 'Colchicine treatment in community healthcare setting to prevent severe COVID-19' by Della-Torre et al 133
Pregnancy in autoimmune rheumatic diseases: the importance of counselling for old and new challenges. 132
Primary antiphospholipid syndrome evolving into systemic lupus erythematosus: may antinucleosome antibodies be predictive? 131
Pregnancy in patients with autoimmune disease: A reality in 2016 131
Long-term neurodevelopmental outcome of children born to prospectively followed pregnancies of women with systemic lupus erythematosus and/or antiphospholipid syndrome 131
Involvement of renal tubular Toll-like receptor 9 in the development of tubulointerstitial injury in systemic lupus. 130
Neonatal effects of maternal antiphospholipid syndrome. 129
Long-term outcome of children born from mothers with autoimmune diseases 129
Development of automated assays for anticardiolipin antibodies determination: addressing antigen and standardization issues. 128
Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome 128
The Efficacy and Safety of Cyclosporin A in Pregnant Patients with Systemic Autoimmune Diseases 127
Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study 127
An EULAR study group pilot study on reliability of simple capillaroscopic definitions to describe capillary morphology in rheumatic diseases 127
Lymphopenia as a risk factor for neurologic involvement and organ damage accrual in patients with systemic lupus erythematosus: A multi-center observational study 127
Low levels of vitamin D are common in primary antiphospholipid syndrome with thrombotic disease. 126
I polimorfismi della metilentetraidrofolatoreduttasi (MTHFR) nel trattamento con methotrexate di pazienti con artrite reumatoide. Revisione della letteratura ed esperienza personale. 124
Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy 124
IL COMPLEMENTO NELLA GRAVIDANZA DI DONNE AFFETTE DA SINDROME DA ANTICORPI ANTIFOSFOLIPIDI PRIMARIA 123
Anti-phospholipid IgG antibodies detected by line immunoassay differentiate patients with anti-phospholipid syndrome and other autoimmune diseases 123
Vitamin D and antiphospholipid syndrome. 122
DOMAIN 1 IS THE MAIN SPECIFICITY OF ANTI-BETA2GPI ANTIBODIES IN SYSTEMIC AUTOIMMUNE DISEASES 122
The 2016 classification criteria for primary Sjogren's syndrome: What's new? 121
Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients 119
METODICHE AUTOMATIZZATE PER ANTICORPI ANTINUCLEO (ANA): E' POSSIBILE SOSTITUIRE L'IMMUNOFLUORESCENZA INDIRETTA? 118
DECREASED TITER OF ANTI-CCP ANTIBODIES AND RHEUMATOID FACTOR AND REDUCTION OF POSTSWITCH MEMORY B CELLS AFTER ABATACEPT TREATMENT FOR RHEUMATOID ARTHRITIS 117
Belimumab decreases flare rate and hinders the expected damage progression in patients with active systemic lupus erythematosus 117
Refractory obstetrical antiphospholipid syndrome: Features, treatment and outcome in a European multicenter retrospective study 116
Small extracellular vesicle-delivered microRNAs promote IFN-alpha secretion by plasmacytoid DCs via TLR7 115
Pathophysiological role and therapeutic implications of vitamin d in autoimmunity: Focus on chronic autoimmune diseases 114
Anti-{beta}2-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their 'innocent' profile? 113
The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study 113
The estimated frequency of Antiphospholipid antibodies in young adults with cerebrovascular events: A systematic review 113
Subpopulations of anti-β₂glycoprotein I antibodies with different pathogenic potential: fine specificity against the domains of β₂glycoprotein I 112
A PROSPECTIVE STUDY IN PREMENOPAUSAL WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS SUPPLEMENTED WITH TWO DIFFERENT REGIMES OF VITAMIN D: EFFICACY AND SAFETY AT SIX MONTHS OF FOLLOW-UP 112
Update on Antiphospholipid Syndrome: Ten Topics in 2017 112
Totale 14.822
Salva come PNG Salva come JPEG
Categoria #
all - tutte 136.817
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 136.817
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.181 0 0 0 0 0 422 113 354 331 473 312 176
2021/20221.763 114 280 54 102 20 102 57 132 103 206 172 421
2022/20231.285 248 16 32 58 125 377 5 107 176 4 65 72
2023/20241.814 108 64 144 158 66 345 56 78 456 33 26 280
2024/20254.520 84 71 66 530 408 411 509 247 392 351 915 536
2025/20265.520 856 1.383 744 1.497 911 129 0 0 0 0 0 0
Totale 27.545